Literature DB >> 3056993

Chronic bullous disease of childhood, childhood cicatricial pemphigoid, and linear IgA disease of adults. A comparative study demonstrating clinical and immunopathologic overlap.

F Wojnarowska1, R A Marsden, B Bhogal, M M Black.   

Abstract

Linear IgA disease of adults, chronic bullous disease of childhood, and the rare childhood cicatricial pemphigoid currently are regarded as separate clinical entities despite their many shared features. All are sulfone-responsive subepidermal bullous diseases associated with linear IgA deposition at the basement membrane zone. In this paper we present a long-term study of 25 cases of adult linear IgA disease, 25 cases of chronic bullous disease of childhood, and four cases of childhood cicatricial pemphigoid, which has revealed further similarities among all three groups. The morphology and distribution of the cutaneous and mucosal lesions were similar; mucosal involvement was present in 80% of patients with adult linear IgA disease, 64% of those with chronic bullous disease of childhood, and 100% of those with childhood cicatricial pemphigoid, and ocular scarring affected patients in all groups. Remission occurred in 64% of those with chronic bullous disease of childhood (the disease was active in 12% after puberty), 48% of those with adult linear IgA disease, and in no cases of childhood cicatricial pemphigoid. HLA B8 and circulating IgA anti-basement membrane zone antibody were more common in chronic bullous disease of childhood than adult linear IgA disease. There were no absolute differences among the three groups, and we suggest that adult linear IgA disease, chronic bullous disease of childhood, and childhood cicatricial pemphigoid are the same disease, with childhood cicatricial pemphigoid being a more severe form of chronic bullous disease of childhood.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3056993     DOI: 10.1016/s0190-9622(88)70236-4

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  32 in total

1.  [Chronic bullous disease of childhood. Long-term therapy over 8 years with 4,4'-diaminodiphenylsulfone].

Authors:  D Pirkhammer; D Zillikens; D Födinger; P Zimmermann; K Rappersberger
Journal:  Hautarzt       Date:  2012-08       Impact factor: 0.751

2.  Linear IgA Bullous Dermatosis: A Rare Clinicopathologic Entity with an Unusual Presentation.

Authors:  Soham Chaudhari; Narciss Mobini
Journal:  J Clin Aesthet Dermatol       Date:  2015-10

3.  Immune-mediated reactions to vancomycin: A systematic case review and analysis.

Authors:  Jasmit S Minhas; Paige G Wickner; Aidan A Long; Aleena Banerji; Kimberly G Blumenthal
Journal:  Ann Allergy Asthma Immunol       Date:  2016-05-04       Impact factor: 6.347

Review 4.  Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations.

Authors:  Khalaf Kridin
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

5.  Chronic bullous dermatosis of childhood: relapse after puberty.

Authors:  I D Hamann; N C Hepburn; J A Hunter
Journal:  J R Soc Med       Date:  1995-05       Impact factor: 5.344

6.  A 62-year-old man with new-onset bullae.

Authors:  August J Generoso; Jordana A Goldman; Alan H Wolff
Journal:  Allergy Asthma Proc       Date:  2021-03-01       Impact factor: 2.587

7.  Drug-induced linear IgA bullous dermatosis after discontinuation of cefuroxime axetil treatment.

Authors:  Maciej Pastuszczak; Sylwia Lipko-Godlewska; Andrzej K Jaworek; Anna Wojas-Pelc
Journal:  J Dermatol Case Rep       Date:  2012-12-31

8.  [Blistering autoimmune diseases of childhood].

Authors:  M Goebeler; D Zillikens
Journal:  Hautarzt       Date:  2002-12-20       Impact factor: 0.751

Review 9.  Cutaneous manifestations in celiac disease.

Authors:  L Abenavoli; I Proietti; L Leggio; A Ferrulli; L Vonghia; R Capizzi; M Rotoli; P L Amerio; G Gasbarrini; G Addolorato
Journal:  World J Gastroenterol       Date:  2006-02-14       Impact factor: 5.742

Review 10.  Bullous Diseases in Children: A Review of Clinical Features and Treatment Options.

Authors:  Brittney Schultz; Kristen Hook
Journal:  Paediatr Drugs       Date:  2019-10       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.